Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
ADAG is expected to report earnings to rise 24.14% to -36 cents per share on August 27
Q2'25
Est.
$-0.36
Q4'24
Beat
by $0.18
Q2'24
Missed
by $0.03
Q4'23
Beat
by $0.96
Q3'23
Missed
by $0.04
The last earnings report on March 24 showed earnings per share of -28 cents, beating the estimate of -46 cents. With 5.59K shares outstanding, the current market capitalization sits at 69.72M.